Japan's Astellas Pharma has seen enough of tivozanib, washing its hands of the once-promising cancer drug and putting an end to a three-year collaboration with Aveo Oncology.
Isis and partner Biogen Idec have kicked off a Phase II study of a spinal muscular atrophy treatment, part of the pair's $300 million alliance to advance antisense treatments.
Novartis may have a long way to go before it's done cutting its blockbuster R&D budget. With a major strategic review underway, Novartis CEO Joe Jimenez told analysts that its massive drug research operation still offers a fresh source of spending cuts--even after a number of moves aimed at concentrating more of its R&D operations in the company's main research hubs in the U.S., Europe and Asia.
Illumina is throwing its cachet and its $1,000 genome sequencing system behind a San Francisco genomics startup incubator backed by Russian billionaire Yuri Milner.
Crowdfunded HIV vaccine developer Immunity Project has gained traction over the past few months, with technology incubator Y Combinator's investment in the initiative sparking mainstream media coverage. The investment raised Immunity Project's profile, but this has brought increased scrutiny of its plans. Not everyone likes what they see.
Sedia Biosciences will use a new $1 million NIH grant to bring forward an HIV diagnostic test it hopes will better assess recently infected individuals and how advanced the virus has become inside the body.
California's Miramar Labs nailed down $10 million in new Series D funding that it will use to boost sales efforts for its CE marked medical device that eliminates sweat glands under the arms. Aisling Capital, Cross Creek Capital, Domain Associates, Morgenthaler Ventures and RusnanoMedInvest all participated in the round.
Researchers have shown in early tests that a nasal vaccine for West Nile virus is effective in mice after two doses as opposed to the traditional three for other vaccines. Currently, no vaccine for the disease is available for humans, despite its recent spread in the U.S. and Canada.
BioDelivery Sciences is looking at a possible $60 million boost to programs in its lineup including the launch of its opioid dependence film Bunavail and continue on the approval path for its pain gel for diabetic neuropathy.
In an interview with Bloomberg, COO John Milligan says the big biotech outfit--which is expected to generate megablockbuster revenue from the newly approved Sovaldi for hep C--is pondering a head-to-head study to determine whether Letairis is better or worse than Actelion's recently approved lung drug Opsumit.